Danazol for paroxysmal nocturnal hemoglobinuria

In: American Journal of Hematology · 1997 · vol. 54(2) , pp. 149–154 · doi:10.1002/(sici)1096-8652(199702)54:2<149::aid-ajh9>3.0.co;2-x · PMID:9034290 · W1984400657
review OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

Danazol therapy improved hematocrit and reduced transfusion needs in four of five patients with paroxysmal nocturnal hemoglobinuria refractory to other treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted > or =2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (30)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-14T06:02:11.780192+00:00
unpaywall
last seen: 2026-10-08T06:33:43.470499+00:00
License: CC0 · commercial use OK